My Application Form Status

Check the status of your application form with Angel Broking.
  • Companies
  • Everything else
Search

Lupin Research Report - 23rd May 2016

Pharmaceutical | Published on May 23rd 2016

IT

For 4QFY2016, Lupin posted results above our expectations. Sales came in at Rs4,091cr (V/s Rs3,665cr expected), up 34.0% yoy. Sales growth was driven by Formulations (Rs3,807.5cr) which rose by 38.6% yoy, while API (Rs283.8cr) witnessed a dip of 7.7% yoy. On the operating front, the EBDITA margin came in at 31.2% V/s 25.1% in 4QFY2015 and V/s our expectation of 29.5%. The expansion in the OPM was on the back of a firmer GPM which came in at 73.8% V/s 67.9% in 4QFY2015 and V/s 72.7% expected. This along with high other income at Rs115cr (V/s Rs41cr in 4QFY2015) led the net profit to come in at Rs807cr V/s Rs547cr in 4QFY2015 and V/s Rs829cr expected. We recommend a Buy on the stock with a price target of Rs1,809. Numbers outperform our expectations: Sales for the quarter came in at Rs4,091cr (V/s Rs3,665cr expected), up 34.0% yoy. Sales growth was driven by Formulations (Rs3,807.5cr) which rose by 38.6% yoy, while API (Rs283.8cr) witnessed a dip of 7.7% yoy. Formulation sales were driven by USA (Rs2,187.1cr, +58.7% yoy), Europe (Rs125.4cr, +40.7% yoy), India (Rs761.5cr, +14.7% yoy, Japan (Rs344.2cr, +17.0% yoy) and ROW (Rs275.8cr, +38.3% yoy). On the operating front, the EBDITA margin came in at 31.2% V/s 25.1% in 4QFY2015 and V/s our expectation of 29.5%. This along with high other income at Rs115cr (V/s Rs41cr in 4QFY2015) led the net profit to come in at Rs807cr V/s Rs547cr in 4QFY2015 and V/s Rs829cr expected. Outlook and valuation: We expect Lupin to post a net sales CAGR of 16.7% to Rs18,644cr and earnings CAGR of 17.2% to Rs69.3/share over FY2016–18E. Currently, the stock is trading at 25.9x and 21.7x its FY2017E and FY2018E earnings, respectively. We recommend a Buy on the stock.

Download Full Report

Accumulate

CMP 1,505
Target Price 1,809
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)67,190.56
MCAP NSE (Rs in Cr)67,208.61
P/E (x)23.81
EPS (Rs.)62.52
BV (Rs.)295.11
Div Yield (%)0.50
FV (Rs.)2.00
P/BV (x)5.38
EV/Sales (x)5.21
EV/EBITDA (x)22.58

Shareholding Pattern (%)

Promoter47.0
Foreign35.0
Public & Others10.0
Institution7.0
Corporate1.0
Grand Total100.0

Trade Securely

AngelEye

Portfolio Tracking & Trading Application View Demo